Salud financiera de hoja de balance de PuraPharm

Salud financiera controles de criterios 3/6

PuraPharm tiene un patrimonio de los accionistas total de HK$130.5M y una deuda total de HK$377.7M, lo que sitúa su ratio deuda-patrimonio en 289.5%. Sus activos y pasivos totales son HK$781.7M y HK$651.3M respectivamente.

Información clave

289.5%

Ratio deuda-patrimonio

HK$377.70m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	HK$51.09m
Patrimonio	HK$130.47m
Total pasivo	HK$651.26m
Activos totales	HK$781.73m

Actualizaciones recientes sobre salud financiera

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Is PuraPharm (HKG:1498) A Risky Investment?

Sep 28

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Nov 02

Is PuraPharm (HKG:1498) A Risky Investment?

Aug 23

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Apr 01

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

Dec 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (HK$305.7M) de 1498 no cubren sus pasivos a corto plazo (HK$510.2M).

Pasivo a largo plazo: Los activos a corto plazo de 1498 (HK$305.7M) superan a sus pasivos a largo plazo (HK$141.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 1498 (250.3%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 1498 ha crecido de 95% a 289.5% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable 1498 tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: 1498 no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 12.3% al año.

Salud financiera de hoja de balance de PuraPharm

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Is PuraPharm (HKG:1498) A Risky Investment?

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Is PuraPharm (HKG:1498) A Risky Investment?

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera